ME00509B - Oblik za terapijsku primjenu aktivnih peptida sa dugotrajnim oslobođenjem aktivnog sastojka i postupak za njihovo dobijanje - Google Patents

Oblik za terapijsku primjenu aktivnih peptida sa dugotrajnim oslobođenjem aktivnog sastojka i postupak za njihovo dobijanje

Info

Publication number
ME00509B
ME00509B MEP-2008-830A MEP83008A ME00509B ME 00509 B ME00509 B ME 00509B ME P83008 A MEP83008 A ME P83008A ME 00509 B ME00509 B ME 00509B
Authority
ME
Montenegro
Prior art keywords
production
sustained release
pharmaceutically active
well
active peptides
Prior art date
Application number
MEP-2008-830A
Other languages
German (de)
English (en)
French (fr)
Inventor
Horst Bauer
Thomas Reissmann
Peter Romeis
Berthold Roessler
Original Assignee
Zentaris Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE10245525A external-priority patent/DE10245525A1/de
Application filed by Zentaris Gmbh filed Critical Zentaris Gmbh
Publication of ME00509B publication Critical patent/ME00509B/me

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Reproductive Health (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Neurosurgery (AREA)
  • Inorganic Chemistry (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Pronalazak se odnosi na farmaceutske oblike za primenu kod kojih je proces oslobadjanja aktivnog sastojka dugotrajan, a koji sadrži bar jedan farmakološki aktivan peptid, kao i na postupak za njihovo dobijanje, kao i na kit koji obuhvata liofilizovani peptid i vodeni rastvor neorganske soli ili soli sirćetne kiseline, kao i na upotrebu vodenog rastvora neorganske soli ili soli sirćetne kiseline u cilju dobijanja farmaceutskog oblika za primenu koji pokazuje odloženo oslobadjanje peptida u toku dužeg vremenskog perioda.
MEP-2008-830A 2002-09-27 2003-09-26 Oblik za terapijsku primjenu aktivnih peptida sa dugotrajnim oslobođenjem aktivnog sastojka i postupak za njihovo dobijanje ME00509B (me)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US41422502P 2002-09-27 2002-09-27
DE10245525A DE10245525A1 (de) 2002-09-27 2002-09-27 Darreichungsform für pharmazeutisch aktive Peptide mit anhaltender Wirkstofffreigabe (sustained release) und Verfahren zu deren Herstellung
DE10320051 2003-04-26
PCT/EP2003/010732 WO2004030650A2 (de) 2002-09-27 2003-09-26 Darreichungsform für pharmazeutisch aktive peptide mit anhaltender wirkstofffreigabe (sustained release) und verfahren zu deren herstellung

Publications (1)

Publication Number Publication Date
ME00509B true ME00509B (me) 2011-10-10

Family

ID=43646377

Family Applications (1)

Application Number Title Priority Date Filing Date
MEP-2008-830A ME00509B (me) 2002-09-27 2003-09-26 Oblik za terapijsku primjenu aktivnih peptida sa dugotrajnim oslobođenjem aktivnog sastojka i postupak za njihovo dobijanje

Country Status (23)

Country Link
US (1) US7884071B2 (me)
EP (1) EP1565160B1 (me)
JP (1) JP4898118B2 (me)
KR (1) KR100633280B1 (me)
CN (1) CN100509053C (me)
AU (1) AU2003287950B2 (me)
BR (1) BRPI0314546B8 (me)
CA (1) CA2507524C (me)
DK (1) DK1565160T3 (me)
ES (1) ES2457019T3 (me)
HK (1) HK1081855A1 (me)
HR (1) HRP20050371B1 (me)
IL (1) IL167415A (me)
IS (1) IS7750A (me)
ME (1) ME00509B (me)
MX (1) MXPA05003318A (me)
NO (1) NO338309B1 (me)
NZ (1) NZ538928A (me)
PL (1) PL208073B1 (me)
RS (2) RS52966B (me)
RU (1) RU2333743C2 (me)
WO (1) WO2004030650A2 (me)
ZA (1) ZA200502150B (me)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5580535B2 (ja) * 2006-01-05 2014-08-27 ノバルティス アーゲー 癌転移および癌転移に関連する骨量減少を予防および処置するための方法
US20070219811A1 (en) * 2006-03-16 2007-09-20 Kim John S Method for using an internet-based CRM application to create an on-line leads marketplace
EP1891964A1 (en) * 2006-08-08 2008-02-27 AEterna Zentaris GmbH Application of initial doses of LHRH analogues and maintenance doses of LHRH antagonists for the treatment of hormone-dependent cancers and corresponding pharmaceutical kits
CA2671925A1 (en) * 2006-12-21 2008-07-10 Stryker Corporation Sustained-release formulations comprising crystals, macromolecular gels, and particulate suspensions of biologic agents
KR101749310B1 (ko) 2008-01-24 2017-06-21 에스퍼란스 파마슈티컬스, 인코포레이티드 용해 도메인 융합 구성물 및 이를 제조하고 사용하는 방법
TWI442932B (zh) 2008-02-11 2014-07-01 Ferring Int Ct Sa 以ＧｎＲＨ拮抗劑治療攝護腺癌的方法
US8324347B2 (en) * 2009-02-24 2012-12-04 Institute For Systems Biology Methods of using halogenated peptides as internal standards for liquid chromatography-mass spectrometry
EP2424503B1 (en) * 2009-05-01 2017-07-05 Ferring BV Composition for the treatment of prostate cancer
WO2011085957A2 (en) 2010-01-13 2011-07-21 Ipsen Pharma S.A.S. Process for the preparation of pharmaceutical compositions for the sustained release of somatostatin analogs
CN102204889B (zh) * 2011-05-23 2013-09-18 蚌埠丰原涂山制药有限公司 一种醋酸地加瑞克冻干粉针剂及其制备方法
AR092840A1 (es) 2012-06-01 2015-05-06 Ferring Bv Elaboracion de degarelix
ITMI20121638A1 (it) * 2012-10-02 2014-04-03 Marco Sbracia Utilizzo di degarelix nel trattamento dell'endometriosi e di patologie ad essa correlate
DK2914633T3 (da) 2012-10-30 2022-03-14 Esperance Pharmaceuticals Inc Antistof/lægemiddel-konjugater og anvendelsesfremgangsmåder
TW201618783A (zh) 2014-08-07 2016-06-01 艾森塔製藥公司 以布魯頓(Bruton)氏酪胺酸激酶(BTK)佔據和BTK再合成速率為基礎之治療癌症、免疫和自體免疫疾病及發炎性疾病之方法
AU2018217064A1 (en) * 2017-01-31 2019-08-08 Veru Inc. Compositions and methods for long term release of Gonadotropin-releasing hormone (GnRH) antagonists
AU2018338924B2 (en) * 2017-09-27 2020-05-21 Novel Pharma Inc. Long-acting palmitic acid-conjugated GnRH derivative, and pharmaceutical composition containing same
US11788642B2 (en) * 2018-01-31 2023-10-17 Zhejiang Sanhua Commercial Refrigeration Controls Co., Ltd. Electric valve and manufacturing method therefor

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5411951A (en) * 1984-10-04 1995-05-02 Monsanto Company Prolonged release of biologically active somatotropin
GB9108634D0 (en) 1991-04-23 1991-06-12 Ciba Geigy Pharmaceutical compositions
US6828415B2 (en) * 1993-02-19 2004-12-07 Zentaris Gmbh Oligopeptide lyophilisate, their preparation and use
DE4305225A1 (de) 1993-02-19 1994-08-25 Asta Medica Ag Neues Herstellverfahren für Cetrorelix Lyophilisat
DE4342091A1 (de) * 1993-12-09 1995-06-14 Asta Medica Ag Erzeugnisse zur Anwendung von initial hohen Dosen von Cetrorelix und Herstellung einer Kombinationspackung zur Verwendung bei Therapie von Krankheiten
US5595760A (en) * 1994-09-02 1997-01-21 Delab Sustained release of peptides from pharmaceutical compositions
US5942493A (en) * 1995-11-28 1999-08-24 Asta Medica Aktiengesellschaft LH-RH antagonists having improved action
US5916582A (en) * 1996-07-03 1999-06-29 Alza Corporation Aqueous formulations of peptides
ATE359805T1 (de) * 1996-08-30 2007-05-15 Peptech Ltd Formulierung zur verzögerten freisetzung von peptidagonisten und -analoga des gnrh
US5968895A (en) * 1996-12-11 1999-10-19 Praecis Pharmaceuticals, Inc. Pharmaceutical formulations for sustained drug delivery
FR2776520B1 (fr) * 1998-03-25 2000-05-05 Sod Conseils Rech Applic Nouvelles compositions pharmaceutiques destinees a la liberation prolongee de peptides et leur procede de preparation
ES2389627T3 (es) * 1998-07-20 2012-10-29 Virbac (Australia) Pty Ltd Formulación para bioimplantes
CO5160256A1 (es) * 1999-02-08 2002-05-30 Zentaris Ag Sales de peptidos farmaceuticamente activos para la liberacion sostenida y proceso de produccion
DE19911771B4 (de) 1999-03-17 2006-03-30 Zentaris Gmbh LHRH-Antagonist, Verfahren zu seiner Herstellung und seiner Verwendung
US7005418B1 (en) * 1999-09-23 2006-02-28 Zentaris Gmbh Method for the therapeutic management of extrauterine proliferation of endometrial tissue, chronic pelvic pain and fallopian tube obstruction
US6635739B2 (en) * 1999-10-15 2003-10-21 Theresa Siler-Khodr Non-mammalian GnRH analogs and uses thereof in regulation of fertility and pregnancy
DE10024451A1 (de) * 2000-05-18 2001-11-29 Asta Medica Ag Pharmazeutische Darreichungsform für Peptide, Verfahren zu deren Herstellung und Verwendung
GB0117057D0 (en) 2001-07-12 2001-09-05 Ferring Bv Pharmaceutical composition
EP1674082A1 (de) * 2004-12-22 2006-06-28 Zentaris GmbH Verfahren zur Herstellung von sterilen Suspensionen oder Lyophilisaten schwerlöslicher basischer Peptidkomplexe, diese enthaltende pharmazeutische Formulierungen sowie ihre Verwendung als Arzneimittel

Also Published As

Publication number Publication date
WO2004030650A2 (de) 2004-04-15
CA2507524C (en) 2012-12-11
PL208073B1 (pl) 2011-03-31
ES2457019T3 (es) 2014-04-24
AU2003287950B2 (en) 2009-01-29
AU2003287950A1 (en) 2004-04-23
NO338309B1 (no) 2016-08-08
US20050282731A1 (en) 2005-12-22
HRP20050371B1 (hr) 2014-09-26
RU2005113163A (ru) 2005-10-10
BRPI0314546B8 (pt) 2021-05-25
PL376446A1 (en) 2005-12-27
KR100633280B1 (ko) 2006-10-16
CN100509053C (zh) 2009-07-08
HK1081855A1 (en) 2006-05-26
JP2006505538A (ja) 2006-02-16
US7884071B2 (en) 2011-02-08
IL167415A (en) 2014-05-28
CA2507524A1 (en) 2004-04-15
WO2004030650A3 (de) 2004-07-15
IS7750A (is) 2005-03-17
RS52966B (en) 2014-02-28
JP4898118B2 (ja) 2012-03-14
BRPI0314546B1 (pt) 2020-04-07
CN1684703A (zh) 2005-10-19
HRP20050371A2 (en) 2005-06-30
BRPI0314546A8 (pt) 2015-12-15
NZ538928A (en) 2006-10-27
RU2333743C2 (ru) 2008-09-20
RS20050247A (en) 2007-06-04
NO20052041L (no) 2005-06-10
BR0314546A (pt) 2005-08-09
EP1565160A2 (de) 2005-08-24
EP1565160B1 (de) 2014-01-22
KR20050084829A (ko) 2005-08-29
ZA200502150B (en) 2005-11-30
DK1565160T3 (da) 2014-04-28
MXPA05003318A (es) 2005-09-12

Similar Documents

Publication Publication Date Title
ME00509B (me) Oblik za terapijsku primjenu aktivnih peptida sa dugotrajnim oslobođenjem aktivnog sastojka i postupak za njihovo dobijanje
AR078558A1 (es) Excipiente estabilizante para una vacuna de virus completo inactivado
PE20100447A1 (es) Solucion acuosa inyectable que contiene 4-[[(7r)-8-isopropil-7-etil-5,6,7,8-tetrahidro-5-metil-6-oxo-tetrahidropteridin-2-il]amino]-3-metoxi-n-[(1-ciclopropil-4-piperazinil)fenil]benzamida
PE20030399A1 (es) Formas de administracion de propiverina o sus sales farmaceuticamente aceptables con liberacion prolongada de la sustancia activa
RS50368B (sr) Levodopa/karbidopa/entakapon farmaceutski preparat
BRPI0713749B8 (pt) formulações oftálmica líquida e não líquida de um antagonista do fator de crescimento endotelial vascular, e, seringa pré-carregada adequada para administração intravítrea
BR0009042A (pt) Composto, uso do mesmo, processo para prepararum composto, composição farmacêutica, e, métodospara tratar uma doença em um animal em que aatividade de cisteìna protease contribui para apatologia e/ou sintomatologia da doença, e paratratar uma doença em um animal em que a atividadede catepsina s contribui para a patologia e/ousintomatologia da doença
RS54670B1 (en) SOLID DOSAGE FORMULATION OF FENTANIL WITH IMPROVED BUCHAL ADSORPTION
RS51746B (sr) Atorvastatin kalcijum u farmaceutskom obliku, njegovoj smeši i farmaceutskoj formulaciji, koja sadrži atorvastatin kalcijum
NO2011006I1 (no) Pitavastin, valgfritt i form av av farmasøytisk akseptabelt salt eller ester
MEP33708A (en) Pharmaceutical compositions comprising a hmg coa reductase inhibitor
CA2504377A1 (en) Pharmaceutical preparation of recombinant factor viii lyophilized without albumin as a stabilizer
WO2007061829A3 (en) Pharmaceutical composition
JP2009516654A5 (me)
HRP20140715T1 (hr) Farmaceutski preparat koji sadrži lipazu bakterijskog porijekla
EE200200504A (et) Farmatseutilised preparaadid
MEP20408A (en) Pharmaceutical dronedarone composition for parenteral administration
HRP20140676T1 (hr) Formulacije deoksikolne kiseline i njezinih soli
HRP20020181B1 (hr) Farmaceutski pripravci koji sadrže derivat benzamida kao aktivan sastojak
MXPA05008403A (es) Uso de acido comestible en formas de dosis solidas farmaceuticas de rapida dispersion.
DE60313998D1 (de) Schmerzfreie injektions-zubereitungen von 2-arylpropionsäuresalzen
AU2003246414A1 (en) Preparations for the intranasal application of selected cgrp antagonists derived from amino acids and a method for their production
ATE516015T1 (de) Galenische form zur oralen transmukosalen zuführung von triptanen
UA83996C2 (ru) Фармацевтическая гелевая композиция пептидов, способ ее получения, набор для ее получения и ее применение
DE602006016168D1 (de) 1,3,5-triazepin-dionen zur Behandlung von Malaria